{"id":19445,"date":"2023-06-13T16:42:00","date_gmt":"2023-06-13T16:42:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4127788_AE27788_0"},"modified":"2023-06-13T16:42:00","modified_gmt":"2023-06-13T16:42:00","slug":"sirnaomics-to-present-latest-developments-on-galahead-therapeutic-platform-at-upcoming-industry-conferences","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=19445","title":{"rendered":"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences"},"content":{"rendered":"<p><span class=\"xn-location\">HONG KONG<\/span>, <span class=\"xn-location\">GERMANTOWN, Md.<\/span> and&nbsp;SUZHOU, <span class=\"xn-location\">China<\/span>, <span class=\"xn-chron\">June 14, 2023<\/span> \/PRNewswire\/ &#8212;&nbsp;<b>Sirnaomics Ltd. <\/b>(the <b>&#8220;Company&#8221;<\/b>; stock code: 2257, together with its subsidiaries, the <b>&#8220;Group&#8221;<\/b> or <b>&#8220;Sirnaomics&#8221;<\/b>)<b>, <\/b>a leading biopharmaceutical company in discovery and development of RNAi therapeutics,&nbsp;today announced that the Company&nbsp;will present the latest developments on GalAhead\u2122, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at three international industry conferences taking place in June: the Precision in Drug Discovery &amp; Preclinical Summit, RNA Therapeutics <span class=\"xn-location\">USA<\/span>, and 19<sup>th<\/sup>&nbsp;Drug Discovery Nexus.<\/p>\n<p>The Company&#8217;s first GalAhead\u2122-based RNAi drug candidate, STP122G, has started a Phase I clinical trial in <span class=\"xn-chron\">May 2023<\/span>. The start of the trial indicates that Sirnaomics&#8217; proprietary GalNAc RNAi platform technology, GalAhead\u2122, has the potential to help patients with high unmet needs in the areas of hematologic, cardiometabolic, immunologic and rare disorders.<\/p>\n<p><b>Precision in Drug Discovery &amp; Preclinical Summit Oral Presentation Details<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Presentation Title<\/b>: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes<\/li>\n<li><b>Presenter<\/b>: <span class=\"xn-person\">Dmitry Samarsky<\/span>, PhD, Sirnaomics Chief Technology Officer<\/li>\n<li><b>Time\/Date<\/b>: <span class=\"xn-chron\">2:55 pm-3:20 pm ET on Tuesday<\/span>, Jun 13, 2023<\/li>\n<li><b>Location<\/b>: Revere Hotel, <span class=\"xn-location\">Boston<\/span>, <span class=\"xn-location\">USA<\/span><\/li>\n<\/ul>\n<p><b>RNA Therapeutics <span class=\"xn-location\">USA<\/span> <\/b><b>Oral Presentation Details<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Presentation Title<\/b>: GalAhead\u2122: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple Genes<\/li>\n<li><b>Presenter<\/b>: <span class=\"xn-person\">Jim Weterings<\/span>, PhD, Sirnaomics Senior Director of Technology Innovation<\/li>\n<li><b>Time\/Date<\/b>: <span class=\"xn-chron\">3:10 pm-3:50 pm ET on Thursday<\/span>, June 15, 2023<\/li>\n<li><b>Location<\/b>: Horton Grand Hotel; <span class=\"xn-location\">San Diego<\/span>, <span class=\"xn-location\">USA<\/span><\/li>\n<\/ul>\n<p><b>19<sup>th<\/sup> Drug Discovery Nexus Oral Presentation Details<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Presentation Title<\/b>: GalAhead\u2122: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes<\/li>\n<li><b>Presenter<\/b>: <span class=\"xn-person\">Jack Wei<\/span>, PhD, Sirnaomics Senior Director of Drug Discovery<\/li>\n<li><b>Time\/Date<\/b>: <span class=\"xn-chron\">3:15 pm -3:40 pm ET on Friday<\/span>, June 16, 2023<\/li>\n<li><b>Location<\/b>: Holiday Inn Express \u2013 Arena Towers; <span class=\"xn-location\">Amsterdam, Netherlands<\/span><\/li>\n<\/ul>\n<p><b><u>About the GalAhead\u2122 Technology<\/u><\/b><\/p>\n<p>The GalAhead\u2122 is a proprietary technology platform for RNAi therapeutics, developed by Sirnaomics. The GalAhead\u2122 platform relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA\u2122 (miniaturized RNAi triggers) and muRNA\u2122 (multi-unit RNAi triggers). mxRNAs\u2122 are comprised of single ~30 nt long oligonucleotides to downregulate individual genes, while muRNA\u2122 molecules are comprised of multiple oligonucleotides to silence two or more targets simultaneously. The targeted delivery technology has demonstrated specific liver hepatocyte targeting via a cell surface receptor ASGPR.<\/p>\n<p><b><u>About Sirnaomics<\/u><\/b><\/p>\n<p>Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical neds and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both <span class=\"xn-location\">Asia<\/span> and <span class=\"xn-location\">the United States<\/span>. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 and STP707. STP122G represents the first drug candidate of GalAhead\u2122 technology entering clinical development. With establishment of the Group&#8217;s manufacturing facility, Sirnaomics currently is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: <a href=\"https:\/\/www.sirnaomics.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.sirnaomics.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HONG KONG, GERMANTOWN, Md. and&nbsp;SUZHOU, China, June 14, 2023 \/PRNewswire\/ &#8212;&nbsp;Sirnaomics Ltd. (the &#8220;Company&#8221;; stock code: 2257, together with its subsidiaries, the &#8220;Group&#8221; or &#8220;Sirnaomics&#8221;), a leading biopharmaceutical company in discovery and development of RNAi therapeutics,&nbsp;today announced that the Company&nbsp;will present the latest developments on GalAhead\u2122, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-19445","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=19445\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences - My Blog\" \/>\n<meta property=\"og:description\" content=\"HONG KONG, GERMANTOWN, Md. and&nbsp;SUZHOU, China, June 14, 2023 \/PRNewswire\/ &#8212;&nbsp;Sirnaomics Ltd. (the &#8220;Company&#8221;; stock code: 2257, together with its subsidiaries, the &#8220;Group&#8221; or &#8220;Sirnaomics&#8221;), a leading biopharmaceutical company in discovery and development of RNAi therapeutics,&nbsp;today announced that the Company&nbsp;will present the latest developments on GalAhead\u2122, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=19445\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-13T16:42:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences\",\"datePublished\":\"2023-06-13T16:42:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445\"},\"wordCount\":527,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445\",\"name\":\"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2023-06-13T16:42:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=19445#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=19445","og_locale":"en_US","og_type":"article","og_title":"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences - My Blog","og_description":"HONG KONG, GERMANTOWN, Md. and&nbsp;SUZHOU, China, June 14, 2023 \/PRNewswire\/ &#8212;&nbsp;Sirnaomics Ltd. (the &#8220;Company&#8221;; stock code: 2257, together with its subsidiaries, the &#8220;Group&#8221; or &#8220;Sirnaomics&#8221;), a leading biopharmaceutical company in discovery and development of RNAi therapeutics,&nbsp;today announced that the Company&nbsp;will present the latest developments on GalAhead\u2122, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=19445","og_site_name":"My Blog","article_published_time":"2023-06-13T16:42:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=19445#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19445"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences","datePublished":"2023-06-13T16:42:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19445"},"wordCount":527,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=19445","url":"https:\/\/transmediavictoria.net.au\/?p=19445","name":"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2023-06-13T16:42:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=19445#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=19445"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=19445#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Sirnaomics to Present Latest Developments on GalAhead\u2122 Therapeutic Platform at Upcoming Industry Conferences"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/19445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19445"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/19445\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}